NEJM original articles

Guest, this browser only · 425 unread · 0 saved · pick a name · updated Nov 20, 6:10 pm

Unread All Saved Clear search

November 5, 2026 Vol. 395 No. 18

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity Jastreboff AM et al. Editorial A Triple Incretin Agonist for Obesity, Osteoarthritis, and Sleep Apnea saved

Background. Retatrutide is a triple-receptor agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.

Methods. In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks. Primary outcomes (evaluated in the 9-mg and 12-mg groups each vs. placebo) were the percent change in body weight and the change in the WOMAC pain score (ranging from 1 to 10, with higher scores indicating worse pain) in the subgroup of 574 participants with knee osteoarthritis and the change in the apnea-hypopnea index in the 243 participants with obstructive sleep apnea. For weight-related end points, intercurrent events were handled by a treatment-regimen estimand (intention-to-treat [ITT]). For end points in participants with knee osteoarthritis or obstructive sleep apnea, a hybrid-treatment estimand was applied, with a hypothetical strategy for intercurrent events suggesting treatment failure; ITT results are also reported.

Results. A total of 2339 participants underwent randomization. The mean percent change in body weight in the retatrutide groups was -17.6% (4-mg dose), -23.7% (9-mg dose), and -25.0% (12-mg dose) versus -3.9% in the placebo group (differences, -19.8 and -21.0 percentage points, respectively; P<0.001 for both comparisons). Among the participants with knee osteoarthritis, the corresponding changes in the pain score in the retatrutide groups for the hybrid estimand were -3.2, -3.5, and -3.6 versus -1.9 with placebo (differences, -1.6 and -1.8 points; both P<0.001); the corresponding changes for the ITT estimand were -3.4, -3.9, and -4.1 versus -2.5 with placebo (differences, -1.4 and -1.6 points; both P<0.001). Among the participants with obstructive sleep apnea, the corresponding changes in events per hour in the retatrutide groups for the hybrid-treatment estimand were -22.9, -34.3, and -31.7 versus -9.9 (differences, -24.4 and -21.9; both P<0.001); the corresponding changes for the ITT estimand were -22.8, -34.3, and -32.1 versus -9.6 (differences, -24.7 and -22.5; both P<0.001). The most common adverse events were gastrointestinal.

Conclusions. In adults with obesity, retatrutide resulted in significant weight reduction, reduced pain in participants with knee osteoarthritis, and reduced apnea-hypopnea events in participants with obstructive sleep apnea. (Funded by Eli Lilly; TRIUMPH-1 ClinicalTrials.gov number, NCT05929066.).

A note or tag saves the article on its own.

Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain Lee KK et al. Editorial From Detection to Action in Computed Tomographic Coronary Angiography saved

Background. Many patients with suspected acute coronary syndrome in whom myocardial infarction has been ruled out in the emergency department remain at risk for cardiovascular events. Whether further investigation reduces this risk is unknown.

Methods. In a multicenter, randomized, controlled trial, patients who presented to an emergency department in 14 hospitals across the United Kingdom were enrolled if myocardial infarction had been ruled out and high-sensitivity cardiac troponin testing indicated an intermediate risk of a cardiovascular event (maximum high-sensitivity cardiac troponin I or T concentration, >5 ng per liter). Participants were randomly assigned in a 1:1 ratio to receive either outpatient computed tomographic (CT) coronary angiography-guided care or standard care. The primary outcome was a composite of myocardial infarction or death from a cardiac cause.

Results. From September 18, 2019, to May 11, 2023, a total of 3170 participants (median age, 61 years; female sex, 30.2%) were assigned to undergo CT coronary angiography (1587 participants) or receive standard care (1583 participants). At 90 days after randomization, CT coronary angiography had been performed in 1462 participants (92.1%) in the CT coronary angiography group and in 35 participants (2.2%) in the standard-care group. Overall, 7 participants (0.4%) had a CT coronary angiography-related adverse event. After a median of 3.0 years, at which point the number of primary-outcome events in the standard-care group exceeded the prespecified minimum of 97, a primary-outcome event had occurred in 112 participants (7.1%) in the CT coronary angiography group and in 116 (7.3%) in the standard-care group (adjusted hazard ratio, 0.95; 95% confidence interval, 0.73 to 1.23; P = 0.71).

Conclusions. In patients with suspected acute coronary syndrome in whom myocardial infarction had been ruled out, routine CT coronary angiography-guided management did not result in a lower incidence of subsequent myocardial infarction or death from a cardiac cause than standard care. (Funded by the British Heart Foundation; TARGET-CTCA ClinicalTrials.gov number, NCT03952351.).

A note or tag saves the article on its own.

Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis Watts GF et al. saved

Background. Severe hypertriglyceridemia is associated with an increased risk of acute pancreatitis. Plozasiran, a small interfering RNA targeting APOC3 messenger RNA, lowers triglyceride levels and potentially mitigates the risk of acute pancreatitis.

Methods. In two double-blind, placebo-controlled trials, 757 adults with severe hypertriglyceridemia were randomly assigned in a 2:1 ratio to receive plozasiran (25 mg) or placebo at baseline and at months 3, 6, and 9. These trials had identical designs, end points, and analytic plans. The primary end point was the percent change in the fasting plasma triglyceride level from baseline to month 12. Key secondary end points were the percent change in the fasting triglyceride level from baseline to month 10, a fasting triglyceride level of less than 500 mg per deciliter (5.6 mmol per liter) and less than 150 mg per deciliter (1.7 mmol per liter), the percent change in the fasting serum triglyceride level at month 12 for patients with a baseline triglyceride level of 880 mg per deciliter or greater, and changes in remnant cholesterol and non-HDL cholesterol. A pooled analysis addressed adjudicated acute pancreatitis, incidence, and first-event timing.

Results. At month 12, patients in the plozasiran groups had a median triglyceride level that was lower than the baseline level by 79% and 81% in the two trials. These reductions corresponded to a median difference in the plozasiran groups as compared with the placebo groups (placebo-adjusted change) of -45 percentage points (95% confidence interval [CI], -51 to -38) and -47 percentage points (95% CI, -54 to -39). A triglyceride level of less than 500 mg per deciliter at 12 months was reported in 91% and 93% of the patients in the plozasiran groups and in 51% and 50% of those in the placebo groups (P<0.001). The rates of acute pancreatitis were 1 per 100 patient-years with plozasiran and 5 per 100 patient-years with placebo (rate ratio, 0.22; P = 0.008). Adverse events during treatment occurred in 73% of the patients in both the pooled plozasiran and placebo groups.

Conclusions. Among patients with severe hypertriglyceridemia, the use of plozasiran resulted in lower triglyceride levels and a lower risk of acute pancreatitis than placebo at 12 months. (Funded by Arrowhead Pharmaceuticals; SHASTA-3 ClinicalTrials.gov number, NCT06347003; SHASTA-4, NCT06347016.).

A note or tag saves the article on its own.

Prevalence of Silent Atherosclerosis across Adult Life Bundgaard H et al. Editorial Atherosclerosis across the Adult Lifespan - A Call to Act from REACT saved

Background. Atherosclerosis may begin in early adulthood and remain clinically silent for decades before cardiovascular disease manifests. Although silent atherosclerosis is associated with cardiovascular events and death independent of traditional cardiovascular disease risk factors, its age- and sex-specific prevalence, vascular territory distribution, and plaque volume across adult life remain incompletely defined.

Methods. We conducted a prospective cohort study in Denmark and Spain. Adults 18 to 70 years of age without known atherosclerotic cardiovascular disease were enrolled in five prespecified age strata that included balanced numbers of women and men. Silent atherosclerosis was assessed at baseline with three-dimensional vascular ultrasonography of the carotid and femoral arteries and with coronary computed tomographic angiography.

Results. A total of 16,808 adults were enrolled in the study. The mean (±SD) age of the participants was 45±12 years, and 51.4% were women. Silent atherosclerosis was present in 57.1% of the participants (95% confidence interval, 56.3 to 58.0). In the youngest age stratum (18 to 29 years), atherosclerosis was present in 8.7% of the men and 6.7% of the women; prevalence increased with age, with a later, steeper midlife rise among women. Among participants in the younger age strata, atherosclerosis was most often peripheral and confined to a single vascular territory; with increasing age, plaque volume increased exponentially and the prevalence of multiarterial involvement became more frequent. Isolated coronary-artery atherosclerosis was uncommon in every age stratum (≤9.3% of men and ≤5.0% of women).

Conclusions. This study of silent atherosclerosis showed that the disease was detectable in early adulthood, with age- and sex-associated increases in prevalence across arterial territories and marked increases in plaque volume. (Funded by the Novo Nordisk Foundation; REACT ClinicalTrials.gov number, NCT06692127.).

A note or tag saves the article on its own.

Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy Barratt J et al. saved

Background. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) have distinct roles in IgA-producing B-cell populations and appear to be central to the pathogenesis of IgA nephropathy. Povetacicept, an enhanced, variant transmembrane activator and calcium-modulator and cyclophilin-ligand interactor (TACI)-Fc fragment fusion therapeutic, is engineered for dual inhibition of BAFF and APRIL.

Methods. In this ongoing, phase 3, double-blind, placebo-controlled trial, participants with biopsy-proven IgA nephropathy receiving stable background therapy were randomly assigned in a 2:1 ratio to receive povetacicept at a dose of 80 mg or placebo subcutaneously every 4 weeks. The primary end point of this prespecified interim analysis was the change in the 24-hour urinary protein-to-creatinine ratio at week 36. Secondary end points were the change at week 36 in galactose-deficient IgA1 levels and hematuria resolution at week 36 among participants with baseline hematuria.

Results. A total of 557 participants received povetacicept (372 participants) or placebo (185 participants). Efficacy analyses included the first 199 participants who had undergone randomization (131 in the povetacicept group and 68 in the placebo group). The 24-hour urinary protein-to-creatinine ratio decreased by 52.0% with povetacicept and by 4.3% with placebo by week 36 (adjusted difference, -49.8 percentage points; 95% confidence interval [CI], -58.6 to -39.2; P<0.001). Galactose-deficient IgA1 levels decreased by 77.4% with povetacicept and increased by 9.1% with placebo (adjusted difference, -79.3 percentage points; 95% CI, -82.2 to -75.9; P<0.001). Among the participants with baseline hematuria, resolution occurred in 85% with povetacicept and in 23% with placebo (adjusted difference, 62 percentage points; 95% CI, 45 to 78; P<0.001). The incidence of adverse events (75% with povetacicept and 78% with placebo) and serious adverse events (3% and 4%, respectively) were similar in the trial groups.

Conclusions. Povetacicept led to a significantly greater reduction in the 24-hour urinary protein-to-creatinine ratio than placebo by week 36 in participants with IgA nephropathy. (Funded by Vertex Pharmaceuticals; RAINIER AIS-D08 ClinicalTrials.gov number, NCT06564142.).

A note or tag saves the article on its own.

3 Perspectives